|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
-
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
According to the letter dated 07.02.2026 from the R&D Incentives Directorate General of the Ministry of Industry and Technology of the Republic of Türkiye, our subsidiary Elixir Pharmaceutical Research and Development Inc. has been granted R&D Center status as of 03.02.2026.
With this status, our subsidiary will be able to benefit from the following deductions, exemptions, supports and incentives under Law No. 5746 on the Support of Research, Development, and Design Activities:
• R&D and design deduction
We respectfully announce this to the public and our investors.
|
||||||||